Literature DB >> 28646744

Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project.

Jacek Niklinski1, Adam Kretowski2, Marcin Moniuszko3, Joanna Reszec4, Anna Michalska-Falkowska5, Magdalena Niemira2, Michal Ciborowski2, Radoslaw Charkiewicz5, Dorota Jurgilewicz6, Miroslaw Kozlowski7, Rodryg Ramlau8, Cezary Piwkowski9, Miroslaw Kwasniewski10, Monika Kaczmarek11, Andrzej Ciereszko11, Tomasz Wasniewski12, Robert Mroz13, Wojciech Naumnik14, Ewa Sierko15, Magdalena Paczkowska2, Joanna Kisluk5, Anetta Sulewska5, Adam Cybulski7, Zenon Mariak16, Boguslaw Kedra17, Jacek Szamatowicz18, Paweł Kurzawa19, Lukasz Minarowski20, Angelika Edyta Charkiewicz21, Barbara Mroczko22, Jolanta Malyszko23, Christian Manegold24, Lothar Pilz24, Heike Allgayer25, Mohammed L Abba26, Hartmut Juhl27, Frauke Koch27.   

Abstract

Personalized and precision medicine is gaining recognition due to the limitations by standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored and individualized treatment for patients based on their clinical characteristics and genetic signatures as well as novel imaging techniques. Advances in whole genome sequencing have led to identification of genes involved in a variety of diseases. Moreover, biomarkers indicating severity of disease or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential and inevitable for translation into personalized medicine, in estimating both, disease risk and response to therapy. Taking into consideration the mostly unsolved necessity of tailored therapy in oncology the innovative project MOBIT (molecular biomarkers for individualized therapy) was designed. The aims of the project are: (i) establishing integrative management of precise tumor diagnosis and therapy including systematic biobanking, novel imaging techniques, and advanced molecular analysis by collecting comprehensive tumor tissues, liquid biopsies (whole blood, serum, plasma), and urine specimens (supernatant; sediment) as well as (ii) developing personalized lung cancer diagnostics based on tumor heterogeneity and integrated genomics, transcriptomics, metabolomics, and radiomics PET/MRI analysis. It will consist of 5 work packages. In this paper the rationale of the Polish MOBIT project as well as its design is presented. (iii) The project is to draw interest in and to invite national and international, private and public, preclinical and clinical initiatives to establish individualized and precise procedures for integrating novel targeted therapies and advanced imaging techniques.
Copyright © 2017 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biobanking; Lung Cancer; Omics; Personalized medicine; Radiomics

Mesh:

Substances:

Year:  2017        PMID: 28646744     DOI: 10.1016/j.advms.2017.05.002

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  8 in total

1.  Metabolomics technology and bioinformatics for precision medicine.

Authors:  Rajeev K Azad; Vladimir Shulaev
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

2.  Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer.

Authors:  Oksana Kowalczuk; Jerzy Laudanski; Wojciech Laudanski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Jacek Niklinski
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

Review 3.  Bridging gaps between images and data: a systematic update on imaging biobanks.

Authors:  Michela Gabelloni; Lorenzo Faggioni; Rita Borgheresi; Giuliana Restante; Jorge Shortrede; Lorenzo Tumminello; Camilla Scapicchio; Francesca Coppola; Dania Cioni; Ignacio Gómez-Rico; Luis Martí-Bonmatí; Emanuele Neri
Journal:  Eur Radiol       Date:  2022-01-10       Impact factor: 5.315

4.  Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare.

Authors:  Polina Mamoshina; Lucy Ojomoko; Yury Yanovich; Alex Ostrovski; Alex Botezatu; Pavel Prikhodko; Eugene Izumchenko; Alexander Aliper; Konstantin Romantsov; Alexander Zhebrak; Iraneus Obioma Ogu; Alex Zhavoronkov
Journal:  Oncotarget       Date:  2017-11-09

5.  Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA).

Authors:  Magdalena Niemira; Francois Collin; Anna Szalkowska; Agnieszka Bielska; Karolina Chwialkowska; Joanna Reszec; Jacek Niklinski; Miroslaw Kwasniewski; Adam Kretowski
Journal:  Cancers (Basel)       Date:  2019-12-21       Impact factor: 6.639

6.  Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

7.  How Should Biobanks Collect Biosamples for Clinical Application? A 20-year Biomarker-related Publication and Patent Trend Analysis.

Authors:  Jae-Eun Lee
Journal:  Osong Public Health Res Perspect       Date:  2018-06

8.  Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Joanna Kisluk; Anna Michalska-Falkowska; Joanna Reszec; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.